Aimmune Therapeutics Inc (AIMT) Given Average Recommendation of “Buy” by Brokerages
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) have been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $49.14.
A number of research analysts have commented on AIMT shares. Cantor Fitzgerald started coverage on Aimmune Therapeutics in a research note on Sunday, December 9th. They set an “overweight” rating and a $23.75 price target on the stock. Credit Suisse Group restated a “buy” rating and set a $40.00 price target on shares of Aimmune Therapeutics in a research note on Tuesday, January 15th. BidaskClub cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. Roth Capital set a $80.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 19th. Finally, Goldman Sachs Group started coverage on Aimmune Therapeutics in a research note on Thursday, December 13th. They set a “neutral” rating and a $32.00 price target on the stock.
NASDAQ:AIMT traded down $0.31 during trading hours on Thursday, reaching $23.34. 544,792 shares of the stock were exchanged, compared to its average volume of 651,935. Aimmune Therapeutics has a twelve month low of $21.22 and a twelve month high of $36.12. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.36 and a beta of -0.11.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
See Also: Consumer Price Index (CPI)
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.